Icosapent ethyl
Icosapent ethyl has been studied in 34 papers since 2009: 7 trials and 2 observational studies in people, 22 reviews; 28 in the past year. It is an approved medicine. The newest paper, Nov 2, 2026: “AI-Derived Coronary CT Plaque Phenotyping as a Predictor of Response to Contemporary Cardiometabolic Pharmacotherapies: A Systematic Review and Meta-Analysis”.
9 new papers in 30 daysSee all 41 papers on icosapent ethyl
At a glance
A human trial reports better hospitalization-free survival with icosapent ethyl in statin-treated patients with cardiovascular disease or diabetes plus another risk factor. One group reports human results, including no clear cerebral blood-flow effect in cognitively unimpaired Veterans. Some trials across uses remain without posted results over a year after ending; companies fund papers, employ authors and sponsor trials.
27 findings in 21 papers from 2009 to 2026, 10 of them since August 2026
The findings reach people, from one lab or study. 8 independent labs in 8 countries; 21 trials, 2 about aging, 5 with no results posted.
“icosapent ethyl treatment was associated with fewer total hospitalizations (HR (95% CI) = 0.91 (0.84, 0.98), P=0.017)”
None of its findings points the other way.
- 8 independent labs in 8 countries
- 21 trials, 2 about aging, 5 with no results posted
- Funders: Amarin Corporation and others
- 4 of 15 findings with company ties
- 8 of 21 trials sponsored by its developers
- Human trial7
- Humans2
- In silico1
Studies in people
See all 7 studies of icosapent ethyl in people7 studies gave icosapent ethyl to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Lowers the risk of cardiovascular disease29-30% risk reduction | Randomized trial | 6,921 peopleGood adherers (took study drug for ≥1.5 years) | ESC Congress 2026 abstract, Oct 26, 2026 |
down: Decreases tissue factormedian 49.4 and 55.8 pg/mL, p=0.046 up: Improves event-free survivallog-rank p=0.022 | Randomized trial2 years | 200 peopleIn high baseline TF patients | ESC Congress 2026 abstract, Oct 26, 2026 |
down: Lowers the risk of hospitalizationHR 0.91, 95% CI 0.84-0.98, P=0.017 up: Improves survival without hospitalizationOR 1.12, 95% CI 1.02-1.22, p=0.016 down: Decreases days lost to hospitalization and deathRR 0.93, 95% CI 0.93-0.94, p<0.001 | Randomized trialmedian 5.0 years | 8,179 people≥50 yearsMidlife adults; Older adults; statin-treated with established cardiovascular disease or diabetes and ≥1 additional risk factor | European journal of preventive cardiology, Jan 16, 2026 |
no change: Has no effect on pTau-217p-value range 0.10 - 0.98 | Randomized trial18 months | 86 peopleMen50-76Midlife adults; Older adults; at risk for dementia | AAIC 2025 abstract, Dec 26, 2025 |
no change: Has no effect on cerebral blood flowMF p: 0.064-0.93; PI p: 0.061-0.94; CBF p: 0.33 | Randomized trial18 months | 123 people50-75Midlife adults; Older adults; cognitively unimpaired Veterans | AAIC 2025 abstract, Dec 25, 2025 |
What did studies of icosapent ethyl find?
18Studies of icosapent ethyl measured 18 outcomes, among them mortality, serious adverse events and total atheroma volume.
Mortality
downin humans1
1 study
Mortality
downin humans1
Icosapent ethyl is linked with lower mortality in humans (FAERS disproportionality analysis, full study period 2012 onward) (ROR 0.495 (95% CI 0.427–0.574)).
“For mortality, IPE showed a reduced overall signal (ROR 0.495, 95% CI: 0.427–0.574)”
HumansFAERS disproportionality analysis, full study period 2012 onward
ESC Congress 2026 abstract
Serious adverse events
downin humans1
1 study
Serious adverse events
downin humans1
Icosapent ethyl is linked with lower serious adverse events in humans (FAERS disproportionality analysis, full study period 2012 onward) (ROR 0.237 (95% CI 0.221–0.256)).
“Icosapent ethyl showed consistently reduced serious adverse event signals across the full study period (ROR 0.237, 95% CI: 0.221–0.256)”
HumansFAERS disproportionality analysis, full study period 2012 onward
ESC Congress 2026 abstract
Total atheroma volume
downin humans1
1 study
Total atheroma volume
downin humans1
Icosapent ethyl decreases total atheroma volume in humans (added to statin therapy, compared with statin-only therapy) (MD -77.50 (95% CI -302.47 to 147.47)).
“Compared with statin-only therapy, the greatest reduction in TAV was observed with IPE (MD -77.50; 95% CI -302.47; 147.47)”
Human trialadded to statin therapy, compared with statin-only therapycoronary arterymean follow-up 19 weeks
ESC Congress 2026 abstract
Event-free survival
upin humans1
1 study
Event-free survival
upin humans1
Icosapent ethyl improves event-free survival in high baseline TF patients (log-rank p=0.022).
“Patients with higher baseline TF demonstrated more favorable event-free survival under IPE treatment”
Human trialin high baseline TF patients
ESC Congress 2026 abstract
Tissue factor
downin humans1
1 study
Tissue factor
downin humans1
Icosapent ethyl decreases tissue factor in humans (median 49.4 and 55.8 pg/mL, p=0.046).
“TF blood levels were reduced after 2 years in IPE-treated patients compared with placebo (median 49.4 and 55.8 pg/mL, p=0.046).”
Human trial2 yearsn = 200
ESC Congress 2026 abstract
Cardiovascular outcomes
upin humans1
1 study
Cardiovascular outcomes
upin humans1
Icosapent ethyl improves cardiovascular outcomes in humans (selected high-risk populations).
“Icosapent ethyl and low-dose colchicine have demonstrated cardiovascular benefit in selected high-risk populations”
Reviewselected high-risk populations
Diagnostics (Basel, Switzerland)
Cardiovascular events
downin reviews1
1 study
Cardiovascular events
downin reviews1
Icosapent ethyl decreases cardiovascular events.
“with icosapent ethyl showing meaningful cardiovascular benefit in the REDUCE-IT trial”
Review
Residual cardiovascular risk beyond LDL-cholesterol control: what remains unaddressed?
American journal of cardiovascular disease
Cardiovascular risk
downin humans1
1 study
Cardiovascular risk
downin humans1
Icosapent ethyl decreases cardiovascular risk in specific populations.
“high-dose purified EPA (icosapent ethyl, 4 g/day) has demonstrated a substantial reduction in residual cardiovascular risk in specific populations.”
Reviewin specific populations4 g/day
Nutrients
Days lost to hospitalization and death
downin humans1RR 0.93
1 study
Days lost to hospitalization and death
downin humans1RR 0.93
Icosapent ethyl decreases days lost to hospitalization and death in humans among those who were hospitalized or died (RR 0.93, 95% CI 0.93-0.94, p<0.001).
“fewer days lost among those who were hospitalized or died (RR (95% CI) = 0.93 (0.93, 0.94), p<0.001)”
Human trialamong those who were hospitalized or died2 g twice dailymedian 5.0 yearsn = 8,179
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT
European journal of preventive cardiology
Survival without hospitalization
upin humans1OR 1.12
1 study
Survival without hospitalization
upin humans1OR 1.12
Icosapent ethyl improves survival without hospitalization in humans (OR 1.12, 95% CI 1.02-1.22, p=0.016).
“Participants randomized to icosapent ethyl were more likely to survive until the end of the study without hospitalization (OR (95% CI) = 1.12 (1.02, 1.22), p=0.016)”
Human trialstatin-treated with established cardiovascular disease or diabetes and ≥1 additional risk factor2 g twice dailymedian 5.0 yearsn = 8,179
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT
European journal of preventive cardiology
pTau-217
no changein humans1
1 study
pTau-217
no changein humans1
Icosapent ethyl showed no clear effect on pTau-217 in humans (at risk for dementia) (p-value range 0.10 - 0.98).
“Compared to placebo, 18 months of IPE therapy did not alter CSF biomarkers of vascular or metabolic health or a marker of AD pathology (pTau‐217)”
Human trialat risk for dementiacerebrospinal fluid4g daily18 monthsn = 86
AAIC 2025 abstract
Cerebral blood flow
no changein humans1
1 study
Cerebral blood flow
no changein humans1
Icosapent ethyl showed no clear effect on cerebral blood flow in humans (cognitively unimpaired Veterans) (MF p: 0.064-0.93; PI p: 0.061-0.94; CBF p: 0.33).
“IPE treatment for 18 months did not significantly change MF, PI, or CBF measures (IPE: n = 41, placebo: n = 44; MF p ‐value range: 0.064‐0.93; PI p ‐value range: 0.061‐0.94; CBF p ‐value: 0.33).”
Human trialcognitively unimpaired VeteransVascepabrain4 g daily18 months
AAIC 2025 abstract
Cerebral blood flow
no changein humans1
1 study
Cerebral blood flow
no changein humans1
Icosapent ethyl showed no clear effect on cerebral blood flow in humans (cognitively unimpaired Veterans) (MF p: 0.064-0.93; PI p: 0.061-0.94; CBF p: 0.33).
“IPE treatment for 18 months did not significantly change MF, PI, or CBF measures (IPE: n = 41, placebo: n = 44; MF p ‐value range: 0.064‐0.93; PI p ‐value range: 0.061‐0.94; CBF p ‐value: 0.33).”
Human trialcognitively unimpaired VeteransVascepa®4 g daily18 months
AAIC 2025 abstract
Menopause-Specific Quality of Life
no changein humans1
1 study
Menopause-Specific Quality of Life
no changein humans1
Icosapent ethyl showed no clear effect on menopause-Specific Quality of Life in humans.
“Menopause-Specific Quality of Life scores improved significantly over time in both groups but no significant differences were noted between them.”
Human trialWomen with hot flashes and moderate to severe psychological distress; compared with placeboenriched ethyl-eicosapentaenoic acid8 weeksfemales
Menopause (New York, N.Y.)
Hot flash frequency
downin humans1
1 study
Hot flash frequency
downin humans1
Icosapent ethyl decreases hot flash frequency in humans (Mean decline of 1.58 hot flashes/day versus 0.50/day with placebo).
“After 8 weeks, HF frequency and score decreased significantly in the E-EPA group compared with the placebo group.”
Human trialWomen with hot flashes and moderate to severe psychological distress; compared with placeboenriched ethyl-eicosapentaenoic acid8 weeksfemales
Menopause (New York, N.Y.)
All 18Fewer
What is icosapent ethyl linked with?
8Studies link icosapent ethyl with 8 measures, among them cardiovascular disease, cardiovascular events and atherosclerotic cardiovascular disease.
Cardiovascular disease
downin humans2
2 studies
Cardiovascular disease
downin humans2
Icosapent ethyl lowers the risk of cardiovascular disease in humans (good adherers (took study drug for ≥1.5 years)) (29-30% risk reduction).
“‘Good adherers’ were defined as participants who took IPE for ≥1.5 years (n=6921), and they experienced a risk reduction of 29-30%.”
Human trialgood adherers (took study drug for ≥1.5 years)4g/dayn = 6,921
ESC Congress 2026 abstract
Icosapent ethyl lowers the risk of cardiovascular disease in patients taking statins who have high triglyceride levels.
“High-dose eicosapentaenoic acid shows substantial benefit in selected patients taking statins who have high triglyceride levels.”
Reviewin patients taking statins who have high triglyceride levels2 g twice a day
Canadian family physician Medecin de famille canadien
Cardiovascular events
downin humans1
1 study
Cardiovascular events
downin humans1
Icosapent ethyl lowers the risk of cardiovascular events in humans (selected patients with atherosclerotic cardiovascular disease).
“Cardiovascular outcome data support icosapent ethyl, low-dose colchicine, dual-pathway antithrombotic therapy, and further ApoB lowering in selected patients.”
Reviewselected patients with atherosclerotic cardiovascular disease
Acta pharmaceutica Sinica. B
Atherosclerotic cardiovascular disease
downin reviews1
1 study
Atherosclerotic cardiovascular disease
downin reviews1
Icosapent ethyl lowers the risk of atherosclerotic cardiovascular disease.
“eicosapentaenoic acid ethyl ester (EPA-EE) as the evidence-based choice for atherosclerotic cardiovascular disease (ASCVD) risk reduction”
Reviewethyl ester
Natural Fish Oil Versus Purified Fish Oil: Composition, Efficacy, and Applications
Journal of nutrition and metabolism
Major ischemic events
downin humans1
1 study
Major ischemic events
downin humans1
Icosapent ethyl lowers the risk of major ischemic events in humans (REDUCE-IT) (17.2% vs. 22.0%; hazard ratio 0.75).
“In REDUCE-IT, icosapent ethyl 4 g/day reduced major ischemic events (17.2% vs. 22.0%; hazard ratio 0.75)”
ReviewREDUCE-IT4 g/day
Omega-3 Fatty Acids in the Management of Cardiovascular Disease Prevention
Cardiovascular drugs and therapy
Atrial fibrillation
upin humans1
1 study
Atrial fibrillation
upin humans1
Icosapent ethyl raises the risk of atrial fibrillation in humans (at pharmacological doses).
“modest but consistent increase in atrial fibrillation risk at pharmacological doses”
Reviewat pharmacological doses
Nutrients
Major adverse cardiovascular events
downin humans1
1 study
Major adverse cardiovascular events
downin humans1
Icosapent ethyl lowers the risk of major adverse cardiovascular events in humans.
“Icosapent ethyl (IPE), a highly purified ethyl ester of eicosapentaenoic acid (EPA), reduces major adverse cardiovascular events (MACE) beyond triglyceride lowering”
Reviewhighly purified ethyl ester
Diabetic medicine : a journal of the British Diabetic Association
Hospitalization
downin humans1HR 0.91
1 study
Hospitalization
downin humans1HR 0.91
Icosapent ethyl lowers the risk of hospitalization in humans (HR 0.91, 95% CI 0.84-0.98, P=0.017).
“icosapent ethyl treatment was associated with fewer total hospitalizations (HR (95% CI) = 0.91 (0.84, 0.98), P=0.017)”
Human trialstatin-treated with established cardiovascular disease or diabetes and ≥1 additional risk factor2 g twice dailymedian 5.0 yearsn = 8,179
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT
European journal of preventive cardiology
Ischemic stroke
downin reviews1
1 study
Ischemic stroke
downin reviews1
Icosapent ethyl lowers the risk of ischemic stroke.
“For triglyceride lowering, recent randomized evidence supports icosapent ethyl for reducing IS risk.”
Review
Dyslipidemia management in stroke prevention: An individualized approach
International journal of stroke : official journal of the International Stroke Society
Has icosapent ethyl been tested in people?
2 of 21 about agingYes: 7 trials and 2 observational studies in people have been published, and 21 trials are registered.
About aging
Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
Phase 2/3Completed
Protective Effect of EPA on Cardiovascular Events
Phase 4Completed
Approved
Jul 26, 2012Angina, Unstable, Cardiovascular Diseases, Myocardial Infarction, Stroke, Severe Hypertriglyceridemia, established cardiovascular disease
Mar 26, 2021Dyslipidemias
Repurposing
Phase 4Completed2 trials
Phase 4Completed3 trials
Phase 3Results posted1 trial
Phase 3Results posted1 trial
Phase 4Status unknown1 trial
Phase 4Completed2 trials
All 26Fewer
Readouts due
- Dec 31, 2026
Stopped
NCT02940223TerminatedFatigue
PI is requesting termination (closure) of this study.
Who is developing icosapent ethyl?
1 company: Mochida Pharmaceutical Company.
- Companies
- Mochida Pharmaceutical CompanyPhase 3hypertriglyceridemia
Trial sponsors
Company1 trialPhase 418,000 people
Company3 trialsPhase 39,110 people
Mochida Pharmaceutical Company
Company1 trialPhase 3316 people
Canadian Medical and Surgical Knowledge Translation Research Group
2 trialsPhase 4170 people
1 trialPhase 4200 people
1 trialPhase 4160 people
China National Center for Cardiovascular Diseases
1 trialPhase 4100 people
Ottawa Heart Institute Research Corporation
1 trialPhase 3168 people
Funding
1 grant since 2018US Department of Veterans Affairs
How this record changed
Summary rewritten as its findings changed.
As it read before
One group reports lower cardiovascular risk among adherent human trial participants; reviews describe cardiovascular benefits and increased atrial fibrillation risk at pharmacological doses. A human trial shows no clear effect on cerebrospinal-fluid pTau-217 in people at dementia risk. Two registered trials address aging; five trials for any use ended over a year ago without posted results; company ties include author affiliation and trial sponsorship.
Summary rewritten as its findings changed.
As it read before
Icosapent ethyl lowers cardiovascular risk in adherent human trial participants, while reviews report increased atrial fibrillation risk at pharmacological doses. One group reports human results, including no clear cerebral-blood-flow effect in cognitively unimpaired Veterans. Two registered trials concern aging; five trials ended over a year ago without posted results, and company ties include a company-affiliated author and Amarin- and Mochida-sponsored trials.
Summary rewritten as its findings changed.
As it read before
Human trials show no clear effect of icosapent ethyl on cerebral blood flow in cognitively unimpaired Veterans or pTau-217 in people at dementia risk. Reviews describe lower cardiovascular risk but increased atrial fibrillation risk at pharmacological doses. One registered trial concerns aging; five across indications ended over a year ago without posted results, and eight have Amarin or Mochida sponsorship.
Summary rewritten as its findings changed.
As it read before
Reviews describe reduced cardiovascular risk with icosapent ethyl at 4 g/day in selected human populations, including fewer major ischemic events, but increased atrial fibrillation at pharmacological doses. Five of 22 registered trials ended over a year ago without posted results or citing papers; eight are sponsored by Amarin Pharma, Mochida Pharmaceutical Company or Zhejiang Doer Biologics.
Summary written from the findings.